[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560277":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":10,"eligibilityCriteria":31,"healthyVolunteers":27,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":38,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"MAXIGESIC",null,"Maxigesig group",{"label":13,"type":10,"description":14,"interventionNames":10},"Ketololac","ketololac group",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"JIN YOUNG BYEON","CONTACT","0220721563","jyb.gsb@gmail.com",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hyeong-Gon Moon","PF.","100560277","seroma-and-hematoma-rates-maxigesic-iv-vs-ketorolac-in-breast-cancer-surgery-100560277",false,"NCT06575049","Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery","Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients","Inclusion Criteria:\n\n* Systemic performance status 0-2 according to ECOG criteria\n* Patients with adequate renal function: serum Cr 1.4 mg\u002FdL or less\n* Patients with adequate liver function Bilirubin, AST\u002FALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal\n* Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)\n* Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)\n* Patients who voluntarily decided to participate in this study and signed a written informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing immediate reconstruction operation\n* Patients with drug allergies to painkillers and anti-inflammatory drugs\n* Patients with a physical condition that would interfere with understanding and submitting the consent form","FEMALE","20 Years","70 Years",{"count":36,"type":37},60,"ESTIMATED","3 Months","OBSERVATIONAL","The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.",[42,43,44,45],"Breast Cancer","Post-Operative Hematoma","Seroma as Procedural Complication","Post-Op Complication","NOT_YET_RECRUITING","2024-09-02",{"date":49,"type":50},"2024-09-19","ACTUAL",{"date":52,"type":37},"2025-05-01",{"date":54,"type":37},"2026-02-20",{"name":5,"class":6}]